TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06667089

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine
Description: The povidone-iodine group will receive a 10% povidone-iodine solution or gel applied directly to the wound after gentle cleaning, with the treatment applied according to a set frequency, typically twice daily. This antiseptic will be left on the wound for a brief period to enhance its antimicrobial action.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: The chlorhexidine group will receive a chlorhexidine solution, usually at a concentration of 0.5% to 2%, applied similarly after cleaning the wound. This solution will remain on the wound according to protocol guidelines, also typically applied twice daily. Both groups will be monitored for adverse reactions, signs of infection, and the overall effectiveness of wound healing throughout the treatment period.
Study: NCT06668363

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treat4All
Description: An alcohol reduction evidence-based intervention integrated with HIV status-neutral counseling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care (control arm)
Description: Sexual risk reduction counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of care (control arm)
Description: Sexual risk reduction counseling
Study: NCT06326476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siplizumab
Description: 40 mg doses
Study: NCT06021769

Intervention type: OTHER
Intervention: Observational only
Description: No intervention
Study: NCT06614738

Intervention type: OTHER
Intervention: Sampling of feces and duodenal fluids
Description: * Blood sampling (plasmotheque and serotheque): 2 tubes (EDTA (5mL) and dry (5mL)) during hospitalization~* Fecal sampling (fecal library): A stool sample (approx. 2g) will be taken 48 hours before the endoscopy at home for outpatient or during hospitalization~* Duodenal aspiration fluid (6-10 mL in total): before and after mucosal lavage with sterile isotonic saline on the day of endoscopy.~* Food and Lifestyle Questionnaire (FFQ) during inclusion
Study: NCT06615609

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smart family doctor
Description: Based on health managers, participants were additionally provided Smart family doctor, which is an AI-assisted applications with personalized interactions. The content includes, but is not limited to: (1) General educational content, covering basic health knowledge on diseases, risk factors, and treatment methods; (2) Targeted health information, such as more specific guidance on blood pressure and blood sugar control, medication adherence, exercise, and smoking cessation; (3) Personalized disease management guidance, providing tailored reminders for patients regarding medication, diet, exercise, and medical visits. Patients can also directly report their latest self-measured blood pressure, blood lipid, blood sugar levels, and medication adherence to receive treatment and medication guidance from the 'Smart family doctor'.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health manager
Description: Participants will received 3-hour health management guidance from a health manager once a week, including guidance on healthy lifestyle, medication treatment, and rehabilitation advice. The research team will provide participants with one smart band, requiring them to wear the band daily to collect health data during the 6-month study period.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health manager
Description: Participants will received 3-hour health management guidance from a health manager once a week, including guidance on healthy lifestyle, medication treatment, and rehabilitation advice. The research team will provide participants with one smart band, requiring them to wear the band daily to collect health data during the 6-month study period.
Study: NCT06614192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-400
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-400
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-400
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine/Tipiracil
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV Infusion
Study: NCT06660290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.003% AR-15512 ophthalmic solution
Description: Investigational ophthalmic solution for topical instillation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REFRESH® Classic ophthalmic solution
Description: Commercially available ophthalmic solution for topical instillation
Study: NCT06614855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C134
Description: Initial Treatment . C134 Dose #1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C134
Description: 2nd Treatment. C134 Dose #2
Study: NCT06614959

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oscillatory Positive Expiratory Pressure (OPEP) Therapy
Description: The smart OPEP device is a standard OPEP device equipped with an additional detachable sensor that collects diagnostic information on the total elapsed time of OPEP use, the pressure generated during use, frequency and amplitude of pressure oscillations, respiratory information (inhalations/exhalation number/time), and sum of all oscillations with a pressure over 1 centimeter of water (cmH2O), all of which will inform the duration and quality of home use.
Study: NCT05691465

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68-DOTATATE
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium Lu 177 Dotatate
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET
Study: NCT06669091

Intervention type: DRUG
Group type: OTHER
Intervention: Ecopipam tablet
Description: A single ecopipam 89.6 mg tablet (equivalent to ecopipam HCl 100 mg)

Intervention type: DRUG
Group type: OTHER
Intervention: Ecopipam tablet
Description: A single ecopipam 89.6 mg tablet (equivalent to ecopipam HCl 100 mg)
Study: NCT05374109

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SYV: Sauti ya Vijana (The Voice of Youth intervention)
Description: Mental health is associated with ART adherence and HIV outcomes. SYV was designed to address the specific challenges of young people living (YPLWH) with HIV in Tanzania. SYV includes 10 group sessions (two sessions held jointly with caregivers) lasting approximately 90 minutes and two individual sessions delivered by trained young adult group leaders who use a manualized protocol that is designed to scale in low resource settings. The intervention is applied to the Social Action Theory (SAT), a theoretical framework used to determine factors that influence health behavior. Building off a SAT resilience framework for YPLWH, components of evidence-based treatment models to influence cognitive, self, and social regulation to improve behavioral health outcomes will be strategically used.
Study: NCT04862468

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Perivascular dexamethasone
Description: Dexamethasone delivery around target vein segment(s)

Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Perivascular sham
Description: Saline delivery around target vein segment(s)
Study: NCT05566639

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix Quadrivalent
Description: Sterile suspension for injection.
Study: NCT05161468

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine injection
Description: 2ml of 1% lidocaine will be drawn into a 3 ml syringe and labeled. It will then be delivered into the AC joint per standard injection procedures (estimated 1-2 ml).
Study: NCT05161468

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid Injection
Description: 1 ml of triamcinolone acetonide (40 mg/ml) will be drawn with 1 ml normal saline into a 3 ml syringe and labeled. It will then be delivered into the AC joint per standard injection procedures (estimated 1-2 ml).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Protein Rich Plasma(PRP) Injection
Description: 30 ml of acid-citrate-dextrose (ACD) will be drawn into a 30 ml syringe to coat the syringe. 3 ml will be left in the syringe and then 27 ml of blood will be drawn via standard venipuncture. The 30 ml mixture of blood and ACD will then be prepared in the Peak PRP system as described in the manufacturer's instruction (PEAK® PRP System). After preparation, PRP will be withdrawn (2 mls) into a 3 ml syringe and labeled. It will then be delivered into the AC joint per standard injection procedures (estimated 1-2 ml).
Study: NCT06605404

Intervention type: DIAGNOSTIC_TEST
Intervention: blood and tissue samples
Description: routine standard of care

Intervention type: DIAGNOSTIC_TEST
Intervention: blood and tissue samples
Description: routine standard of care

Intervention type: DIAGNOSTIC_TEST
Intervention: blood and tissue samples
Description: routine standard of care
Study: NCT05934396

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT) Worksheets
Description: The researchers will provide instructions for participants to complete a packet of worksheets teaching introduction to cognitive behavioral therapy (CBT), affect regulation, cognitive restructuring, and problem solving.
Study: NCT06605404

Intervention type: DIAGNOSTIC_TEST
Intervention: blood and tissue samples
Description: routine standard of care

Intervention type: DIAGNOSTIC_TEST
Intervention: blood and tissue samples
Description: routine standard of care

Intervention type: DIAGNOSTIC_TEST
Intervention: blood and tissue samples
Description: routine standard of care

Intervention type: DIAGNOSTIC_TEST
Intervention: blood and tissue samples
Description: routine standard of care

Intervention type: OTHER
Intervention: blood and tissue samples
Description: Routine standard of care

Intervention type: OTHER
Intervention: blood and tissue samples
Description: Routine standard of care

Intervention type: OTHER
Intervention: blood and tissue samples
Description: Routine standard of care

Intervention type: OTHER
Intervention: blood and tissue samples
Description: Routine standard of care

Intervention type: OTHER
Intervention: blood and tissue samples
Description: Routine standard of care

Intervention type: OTHER
Intervention: blood and tissue samples
Description: Routine standard of care

Intervention type: OTHER
Intervention: blood and tissue samples
Description: Routine standard of care
Study: NCT06606925

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: fMRI with virtual reality flight simulator
Description: During this scan, the subject will be wearing the stereogenic goggles called the Visual System HD (NordicNeuroLab) mounted in the scanner via a headcoil that can be adjusted to the subject's comfort using the control arm and completely cover the eyes to prevent light exposure and to clearly visualize eye movement during the flight simulation. The subject will be using a visual response system with customized grips to simulate a stick and throttle in a jet cockpit while visualizing the flight simulation (PICT) in the goggles.
Study: NCT05846789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC Chemotherapy
Description: SOC Chemotherapy will be given AUC 6 IV q3 weeks for a maximum of 9 infusions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOC Chemotherapy
Description: SOC Chemotherapy will be given AUC 6 IV q3 weeks for a maximum of 9 infusions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC Chemotherapy
Description: SOC Chemotherapy will be given AUC 6 IV q3 weeks for a maximum of 9 infusions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOC Chemotherapy
Description: SOC Chemotherapy will be given AUC 6 IV q3 weeks for a maximum of 9 infusions.
Study: NCT06538220

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires and focus group
Description: To evaluate the Chronic Disease Unit care pathway, patients will respond to questionnaires : quality of life (SF-12), personal efficacy scale (GSES), Specific self Efficacy related to Weight Management (SEWM), Rosenberg self-esteem, body image satisfaction (QIC), state of anxiety and depression (HAD), Chronic Disease Unit satisfaction. Some patients will also participate to focus group.
Study: NCT05520060

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical support
Description: Pharmacological and non-pharmacological methods in pain management, Mobilization, Position preferred by the woman, Fluid and nutritional support, Massage applications, Sacral pressure, Listening to music, Breathing and relaxation exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychospiritual support
Description: Effective communication, Encouragement to speak up and express fears, Support for faith-oriented practices

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Environmental and sociocultural support
Description: egulating the temperature, light and sound of the room, Environment that promotes respect for privacy, Reducing environmental noise, Information, Social support, Talking about cultural practices, Social support

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Routine care
Description: Admission to the delivery room, preparation for birth, delivery, postpartum care, etc.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine care
Description: Admission to the delivery room, preparation for birth, delivery, postpartum care, etc.
Study: NCT05860452

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine
Description: single shot bilateral TAP block

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: single shot bilateral TAP block
Study: NCT06671093

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Tune-401
Description: Epigenetic gene silencing therapy

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Tune-401
Description: Epigenetic gene silencing therapy

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Tune-401
Description: Epigenetic gene silencing therapy

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Tune-401
Description: Epigenetic gene silencing therapy
Study: NCT06673017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTM-101
Description: PTM-101, an absorbable drug product containing paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTM-101
Description: PTM-101, an absorbable drug product containing paclitaxel
Study: NCT06673056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl-L-Leucine
Description: N-Acetyl-L-Leucine is a modified amino-acid ester that is orally administered (granules for suspension in a sachet)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo Sachet
Study: NCT06671184

Intervention type: OTHER
Intervention: Observations on clinicopathological factors influencing the difficulty of surgery
Description: Age, body mass index, gender, thyroid function parameters, lesion size, lesion location, ultrasound data

Intervention type: OTHER
Intervention: Observations on clinicopathological factors influencing the difficulty of surgery
Description: Age, body mass index, gender, thyroid function parameters, lesion size, lesion location, ultrasound data
Study: NCT05010577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BX004-A
Description: Combination of nebulized bacteriophages targeting Pseudomonas aeruginosa
Study: NCT05704595

Intervention type: OTHER
Group type: OTHER
Intervention: Initial outpatient management strategy, including outpatient IV diuretics in clinic
Description: Management strategy including IV diuretic in the outpatient clinic

Intervention type: OTHER
Group type: OTHER
Intervention: Initial hospitalization-based management strategy
Description: Direct admission to the hospital
Study: NCT06615726

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regular physical activity
Description: Best medical treatment plus regular physical activity. Each subject is equipped with an exercise guidance expert to regularly guide and adjust the exercise plan according to the subject's personal conditions throughout the trial period. After randomization, the exercise guidance expert formulated an individualized aerobic exercise plan based on the subject's preferences and their own exercise abilities. After each exercise, subjects filled out the exercise diary , and reported back to the exercise guidance expert.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Best medical treatment
Study: NCT06616324

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Participants in the intervention group will undergo ESWL according to standard treatment but with the addition of Virtual Reality and ANC-headphones as a supplement.
Study: NCT05564273

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: VIOME Precision Nutrition Program
Description: Precision supplement based on the participants microbiome sample results. Participants in this arm may receive supplements, diet recommendations, and app coaching.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: VIOME-designed condition-based supplements
Description: Pre-formulated supplements based on overall health conditions. Participants in this arm may receive supplements, diet recommendations, and app coaching.
Study: NCT06667141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACR-2316
Description: ACR-2316 is an experimental drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACR-2316
Description: ACR-2316 is an experimental drug
Study: NCT06668636

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ED-PATCH
Description: Participants will access ED-PATCH using their personal mobile device and use it to track important information throughout their visit. The summary will be checked by a healthcare provider and corrected, if necessary, before being locked and sent to the patient or caregiver to keep for their own records.
Study: NCT06613360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLN-978
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLN-978
Description: Specified dose on specified days
Study: NCT05010577

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nebulized placebo
Study: NCT06064929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Felzartamab
Description: Specified dose on specified days
Study: NCT06469138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemcentinib
Description: Each 200 mg dose contains approximately 32.8 μCi (1.21 MBq) of 14C-bemcentinib and is administered as a single dose on Day 1 of the study.
Study: NCT06195163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Gel in Sachet Dosage Form
Description: Transdermal testosterone gel application prior to ovarian stimulation in the study group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No pretreatment
Description: No pretreatment prior to the ovarian stimulation in the control group.
Study: NCT06057909

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: Test that looks at the structure of the brain.
Study: NCT05846789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizimab 8 mg/ actual body weight in kg IV q4 weeks
Study: NCT06057909

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: Test that looks at the structure of the brain.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: Test that looks at the structure of the brain.

Intervention type: DIAGNOSTIC_TEST
Intervention: Electroencephalography
Description: Non-invasive technique to measure brain waves
Study: NCT05833295

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Downhill walking
Description: Change in the H/M ratio after a downhill walk.
Study: NCT06057909

Intervention type: DIAGNOSTIC_TEST
Intervention: Electroencephalography
Description: Non-invasive technique to measure brain waves

Intervention type: DIAGNOSTIC_TEST
Intervention: Electroencephalography
Description: Non-invasive technique to measure brain waves

Intervention type: DIAGNOSTIC_TEST
Intervention: Electromyography
Description: Technique to evaluate muscle activity

Intervention type: DIAGNOSTIC_TEST
Intervention: Electromyography
Description: Technique to evaluate muscle activity

Intervention type: DIAGNOSTIC_TEST
Intervention: Electromyography
Description: Technique to evaluate muscle activity
Study: NCT06674811

Intervention type: OTHER
Intervention: Wearing Smartwatch
Description: Patients and their caregivers will be asked to start wearing a smartwatch prior to surgery and continuing to wear it for one year following surgery at all times except when bathing or swimming, eating, undergoing a procedure, or if refusing to wear them. The smartwatches collect motor activity by minutes spent being sedentary, active, or highly active, heart rate, and sleep duration and stages. Data from the smartwatches syncs with Garmin connect using Fitabase to allow the study team to review the data.

Intervention type: OTHER
Intervention: Wearing Smartwatch
Description: Patients and their caregivers will be asked to start wearing a smartwatch prior to surgery and continuing to wear it for one year following surgery at all times except when bathing or swimming, eating, undergoing a procedure, or if refusing to wear them. The smartwatches collect motor activity by minutes spent being sedentary, active, or highly active, heart rate, and sleep duration and stages. Data from the smartwatches syncs with Garmin connect using Fitabase to allow the study team to review the data.
Study: NCT05833295

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Downhill walking
Description: Change in the H/M ratio after a downhill walk.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Walking on flat ground
Description: Change in the H/M ratio after a Walking on flat ground